预约演示
更新于：2025-05-28
Tenofovir
替诺福韦
更新于：2025-05-28
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2008-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H16N5O5P |
InChIKeyPINIEAOMWQJGBW-FYZOBXCZSA-N |
CAS号206184-49-8 |
关联
263
项与 替诺福韦 相关的临床试验NCT03304717
Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome
CTRI/2024/08/072599
A retrospective analysis of adherence rate and associated factors in a Tenofovir, Lamivudine, and Dolutegravir based regimen in People Living with HIV - NIL
NCT06602622
Change in Body Weight and BMI in PWH Virologically Suppressed Who Maintain a Second-generation INSTI Regimen Compared to Those Who Switch to DOR/3TC/TDF At 48 Weeks
100 项与 替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 替诺福韦 相关的专利（医药）
登录后查看更多信息
6,352
项与 替诺福韦 相关的文献（医药）2025-12-31Global Health Action
Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care
Article
作者: Abdissa, Alemseged ; Björkman, Per ; Abdulahi, Ilili Jemal ; Reepalu, Anton ; Elvstam, Olof ; Medstrand, Patrik
BACKGROUND:
Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited.
OBJECTIVE:
To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia.
METHODS:
We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019-2020 as having either suppression (<150 copies/mL) or low-level viremia (151-1,000 copies/mL); people with >1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up.
RESULTS:
Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2-6.2) and attrition (aOR, 3.4; 95% CI, 1.7-6.6).
CONCLUSION:
Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.
2025-07-01Journal of Clinical and Experimental Hepatology
Efficacy and Safety of Tenofovir Plus Entecavir Combination Therapy Versus Tenofovir Monotherapy in Chronic Hepatitis B Virus Patients With Resistance or Partial Response to Entecavir: A Systematic Review and Meta-analysis
Review
作者: Dalal, Priyal ; Ahluwalia, Arjun ; Bharadwaj, Hareesha R ; Shah, Muhammad H ; Gopakumar, Harishankar ; Roy, Sakshi ; Ali, Syed H ; Gaur, Aditya ; Rao, Medha S ; Tan, Joecelyn K ; Fuad, Muhtasim ; Dhali, Arkadeep
Background and objectives:
Chronic hepatitis B virus remains a significant cause of liver disease in the developing world, leading to sequelae such as hepatocellular carcinoma. While entecavir (ETV) serves as a first-line treatment, its growing resistance rates underscore the need to explore viable alternatives. Tenofovir disoproxil fumarate (TDF) monotherapy and entecavir plus tenofovir (TDF + ETV) combination therapy are both employed as treatments, but one's efficacy over another is in question. This meta-analysis aims to investigate any primacy of either treatment.
Methods:
We conducted a comprehensive literature search across PubMed/Medline, Embase, Cochrane Central, Web of Science, and China National Knowledge Infrastructure from inception till 7th October 2024. Studies comparing the safety and efficacy of TDF monotherapy versus TDF + ETV combination therapy in patients resistant to entecavir were considered. Data about the virologic response (VR), virologic breakthrough, HbeAg seroconversion, HbeAg/HbsAg seroclearance, and alanine aminotransferase normalization were extracted. Relative risks (RRs) and their corresponding 95% confidence intervals (CIs) were calculated, pooled, and analyzed in a random-effects model. P-value <0.05 was regarded as significant for all analyses.
Results:
Nine studies, comprising 335 patients undergoing monotherapy and 352 patients undergoing combination therapy, satisfied the criteria. TDF + ETV combination therapy was found slightly advantageous to TDF monotherapy, stimulating a VR at 48 weeks (RR 1.081 95% CI: [1.001-1.167] P = 0.046, I2 = 0%), along with the HbeAg seroconversion rate (RR 1.711 95% CI: [1.005-2.913] P = 0.048, I2 = 0%). There were no significant adverse events in individual studies to warrant a meta-analysis.
Conclusions:
TDF + ETV shows slightly better efficacy to TDF monotherapy over a 48-week treatment regimen, with minimal safety concerns. However, further high-quality studies like randomized controlled trials are needed to further solidify conclusions, with this meta-analysis only achieving borderline significances.
Registration:
This review is registered on the PROSPERO database (ID: CRD42024581443).
2025-07-01WATER RESEARCH
Dissociation-dependent kinetics and distinct pathways for direct photolysis and •OH/SO4•− radical dominated photodegradation of ionizable antiviral drugs in aquatic systems
Article
作者: Halsall, Crispin ; Zheng, Jinshuai ; Niu, Junfeng ; Ge, Linke ; Zhang, Peng ; Cui, Nannan
Advanced oxidation processes (AOPs), such as UV, UV/H2O2 and UV/persulfate, are widely used to remove emerging organic contaminants from wastewater streams. However, knowledge on chemical degradation pathways, reaction kinetics as well as formation and toxicity of key degradates is limited. We investigated the direct photolysis and •OH/SO4•- dominated kinetics, intermediates and toxicity evolution of three ionizable antiviral drugs (ATVs): tenofovir (TFV), didanosine (DDI), and nevirapine (NVP). Their transformation kinetics were found to depend on the dominant protonated states. Under UV-Vis irradiation (λ > 290 nm), TFV and DDI photolyzed the fastest in the cationic forms (H2TFV+ and H2DDI+), whereas NVP exhibited the fastest photodegradation in the anionic forms (NVP-). The anionic forms (TFV- and NVP-) demonstrated the highest reactivities towards •OH in most cases, while the cationic forms (H2DDI+ and H2NVP+) reacted the fastest with SO4•- for most of the ATVs. The dissociation-dependent kinetics can be attributed to the discrepancies in deprotonation degrees, quantum yields, electron densities and coulombic repulsion with SO4•- in their dissociated forms. Based on the key product identification via HPLC-MS/MS, the pathways involved hydroxylation, dehydroxylation, oxidation, reduction, cyclopropyl cleavage, C-N breaking, elimination, cyclization and deamidation reactions, which can be prioritized based on the specific compound and the photochemical process. Furthermore, a bioassay showed the photomodified toxicity of the ATVs to Vibrio fischeri (bioluminescent bacteria) during the three processes, which was also demonstrated by ECOSAR model assessment. Nearly half of the chemical intermediates were demonstrably more toxic than their respective parent ATVs. These results provide new insights into understanding the persistence, fate and hazards associated with applying the UV-assisted AOPs to treat wastewater containing ATVs.
100 项与 替诺福韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 病毒感染 | 中国 | 2008-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乙型肝炎病毒相关肝细胞癌 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 慢性乙型肝炎 | 临床3期 | 中国台湾 | 2012-09-01 | |
| 单纯疱疹 | 临床3期 | 南非 | 2011-10-01 | |
| HIV感染 | 临床3期 | 比利时 | 2002-07-16 | |
| HIV感染 | 临床3期 | 加拿大 | 2002-07-16 | |
| HIV感染 | 临床3期 | 法国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 德国 | 2002-07-16 | |
| HIV感染 | 临床3期 | 意大利 | 2002-07-16 | |
| HIV感染 | 临床3期 | 葡萄牙 | 2002-07-16 | |
| HIV感染 | 临床3期 | 西班牙 | 2002-07-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tenofovir therapy (TAF) | 廠願廠鏇餘簾遞廠膚鹽(廠鹽鬱鏇遞構艱鑰夢廠): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | Tenofovir therapy (TAF) | 窪窪餘鬱鹽選衊鏇願繭(夢鬱憲選網鹹醖齋壓願): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | Tenofovir therapy (TAF) | 蓋鹹壓鏇鬱願淵觸襯窪(夢範遞廠壓獵鹽繭艱鑰): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | PrEP (Usual clinic flow) | 淵遞齋餘獵襯醖獵獵鏇(繭鬱構鏇鹽鹹選範衊艱) = 簾蓋顧網遞蓋鏇餘積餘 製製選艱觸窪鏇廠憲遞 (糧築窪壓顧觸顧網遞艱 ) 更多 | - | 2024-03-01 | ||
N/A | 330 | Tenofovir dis-oproxil fumarate (TDF) | 積繭夢願艱淵築鹽遞壓(遞鏇獵簾壓願壓蓋築範) = 鏇網壓獵蓋構餘憲夢願 鹽淵遞遞顧壓鹹淵齋鏇 (鏇鏇鏇範壓糧鏇積壓鬱 ) 更多 | - | 2023-11-10 | ||
N/A | 3,384 | 襯網鹹艱獵淵壓範鏇鹹(鬱壓獵簾廠壓廠憲製築) = 淵鏇鬱夢選窪構網築廠 選餘憲築廠鹹顧齋範壓 (膚顧選構顧選鹹繭鹽築 ) 更多 | - | 2023-11-10 | |||
Entecavir (ETV) | 襯網鹹艱獵淵壓範鏇鹹(鬱壓獵簾廠壓廠憲製築) = 醖製顧壓糧繭獵襯壓壓 選餘憲築廠鹹顧齋範壓 (膚顧選構顧選鹹繭鹽築 ) 更多 | ||||||
临床1期 | 8 | 鹽襯鹽憲積鹹窪淵壓廠(觸蓋遞廠繭簾餘膚觸鑰) = 製鹹簾繭製網鹹醖憲鬱 鑰繭齋艱窪鹽衊糧鹽襯 (鑰夢鬱製願衊鬱選鹹憲, 醖糧範鬱鬱膚糧襯選餘 ~ 壓繭網餘獵鬱衊網憲廠) 更多 | - | 2023-10-30 | |||
临床1期 | 10 | 觸餘夢鬱築醖鑰廠糧製(觸繭衊顧選鬱鏇鏇築遞) = 鬱淵鹹遞築製憲憲糧壓 積鑰簾夢鬱齋齋夢簾夢 (壓製壓齋遞顧積鬱鏇製, 819.0428) 更多 | - | 2023-04-12 | |||
N/A | - | 觸積蓋積醖蓋範糧鹹衊(簾襯繭繭簾範壓範餘艱) = 鬱繭願壓鹽鹽糧齋觸夢 築夢夢觸簾餘窪淵鬱觸 (餘夢鏇衊顧範蓋遞齋襯 ) | - | 2023-03-01 | |||
N/A | 201 | Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a | 壓簾遞廠鏇鬱製衊積廠(壓夢築顧選獵醖觸鬱簾) = 構鑰構膚廠範構憲積壓 窪獵衊鬱醖淵餘願選壓 (繭顧選艱壓獵願獵鏇艱 ) | - | 2023-01-05 | ||
Tenofovir disoproxil fumarate (TDF) alone | 壓簾遞廠鏇鬱製衊積廠(壓夢築顧選獵醖觸鬱簾) = 憲蓋鏇積築網膚築獵糧 窪獵衊鬱醖淵餘願選壓 (繭顧選艱壓獵願獵鏇艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用